{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:00:51Z","timestamp":1792670451772,"version":"4.5.0"},"reference-count":116,"publisher":"Baishideng Publishing Group Inc.","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4254\/wjh.v9.i21.907","type":"journal-article","created":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T07:00:30Z","timestamp":1501398030000},"page":"907","source":"Crossref","is-referenced-by-count":167,"title":["Chemotherapy for hepatocellular carcinoma: The present and the future"],"prefix":"10.4254","volume":"9","author":[{"given":"Marco","family":"Le Grazie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Tarocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Polvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/00034240"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.021"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.021"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0844"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.199"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0393-4"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0013"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707498104"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182468039"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27543"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02940.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12352"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Marrero JA, Lencioni R, Ye SL, Kudo M, Bronowicki JP, Chen X, Dagher L, Furuse J, Geschwind JF, Ladr\u00f2n de Guevara L. Final analysis of GIDEON (Global Investigation of therapeutic decision in hepatocellular carcinoma [HCC] and of its treatment with sorafenib [sor]) in &gt; 3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction. J Clin Oncol 2013;31:4126.","DOI":"10.1200\/jco.2013.31.15_suppl.4126"},{"key":"ref19","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary cancers (Accessed version 2, 2015). Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf<\/ext-link>."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0192"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.014"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12286"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2136-1"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00198-9"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000365993"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000367743"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000343875"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.05.007"},{"key":"ref30","unstructured":"Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study. J BUON 2017;22:150-156."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5604\/16652681.1231583"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15075"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181d31ed2"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i42.7316"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4410"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3009"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27290"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.8372"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.3298"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.7746"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7189"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00050-9"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.181"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24450"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Ikeda K, Kumada H, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Suzuki T, O\u2019Brien JP, Okita K. M Phase I\/II trial of lenvatinib (E7080), a multi-targeted tyrosin kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol 2012;23:abstr 737P.","DOI":"10.1016\/S0923-7534(20)33318-4"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Veralype C, Cohn AL, Kelley RK, Yang T, Su W, Ramies DA, Lee Y, Shen X, Van Cutsem F. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a Phase II randomized discontinuation trial (RDT). J Clin Oncol 2012;30:abstract 4007.","DOI":"10.1200\/jco.2012.30.4_suppl.261"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70490-4"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. J Clin Oncol 2014;32:abstract 4019.","DOI":"10.1200\/jco.2014.32.15_suppl.4019"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3445"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Yau T, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpaijt T, Lencioni R, Camp AC, Cox DS. A phase I\/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2012;30:abstract 4108.","DOI":"10.1016\/S0168-8278(11)60667-3"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Qin S, Cheng AL, Lim HY, Xu L, Bladt F, Johne A, Li C, Zheng H, Massimini G. A multicenter, randomized, phase Ib\/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET ) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function. J Clin Oncol 2014;32:abstract TPS4151.","DOI":"10.1200\/jco.2014.32.15_suppl.tps4151"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Bang YJ, Su WC, Nam DH, Lim WT, Bauer TM, Brana I, Poon RTP, Hong DS, Lin CC, Peng B. Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. J Clin Oncol 2014;32:abstract 2520.","DOI":"10.1200\/jco.2014.32.15_suppl.2520"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"O\u2019Neill BH, Bendell JC, Modiano MR, Machiels JPH, Versola MJ, Hodge JP, Sawarna K, Tse N. Phase I\/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results. J Clin Oncol 2013;31:abstract 94.","DOI":"10.1200\/jco.2013.31.4_suppl.294"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1418"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Faivre SJ, Santoro A, Kelly RK, Merle P, Gane E, Douillard JY, Waldschmidt D, Mulcahy MF, Costentin C, Minguez B. A phase 2 study of a novel transforming growth factorbeta (TGF-{beta} 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2014;32:abstract LBA173.","DOI":"10.1200\/jco.2014.32.3_suppl.lba173"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0793"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv388"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1148-3"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Kudo M, Moriguchi M, Numata K, Hidaka H, TanakaH , Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Okusaka T. A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE). J Clin Oncol 2015;33:abstr 4018.","DOI":"10.1200\/jco.2015.33.15_suppl.4018"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Kudo M, Okusaka T, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M. Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial. J Clin Oncol 2016;34:abstr 229.","DOI":"10.1200\/jco.2016.34.4_suppl.229"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.5643"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0190"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.006"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0100-y"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603956"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Chia WK, Ong S, Toh HC, Hee SW, Choo SP, Poon DY, Tay MH, Tan CK, Koo WH, Foo KF. Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore 2008;37:554-558.","DOI":"10.47102\/annals-acadmedsg.V37N7p554"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp010"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2014.04.031"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9634-4"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1672"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R, Murray JJ, Bekaii-Saab TS. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol 2016;34:abstract 192.","DOI":"10.1200\/jco.2016.34.4_suppl.192"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Assenat E, Boige V, Th\u00e9zenas S, Pageaux GP, Peron JM, Becouam Y, Dahan L, Merle P, Blane HF, Bouche O. Sorafenib alone versus sorafenib combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER\/FFCD PRODIGE 10 trial). J Clin Oncol 2013;31:abstract 4028.","DOI":"10.1200\/jco.2013.31.15_suppl.4028"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0796-5"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Yau T, Cheung FY, Lee F, Choo SP, Wong H, Toh HC, Leung AK, Chan P, Yau TK, Wong J. A multi-center phase II study of sorafenib, Capecitabine and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study. J Clin Oncol 2013;31:abstract 4117.","DOI":"10.1200\/jco.2013.31.15_suppl.4117"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2008.00338.x"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Ikeda M, Shimizu S, Sato T, Morimoto M, Inaba Y, Kojima Y, Hagihara A, Kudo M, Nakamori S, Kaneko S. Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: a randomized phase II trial. J Clin Oncol 2015;33:abstr 4076.","DOI":"10.1200\/jco.2015.33.15_suppl.4076"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Kudo M, Ueshima K, Yokosuka O, S Obi, N Izumi, H Aikata, H Nagano, E Hatano, Y Sasaki, K Hino, T Kumada, K Yamamoto, Y Imai, S Iwadou, C Ogawa, T Okusaka, Y Arai, F Kanai, K Akazawa, and SILIUS Study Group. Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin\/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. J Hepatol 2016;64:abstr LB04.","DOI":"10.1016\/S0168-8278(16)00173-2"},{"key":"ref80","unstructured":"Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013;13:5."},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Duffy AG, Makarova-Rusher OV, Kerkar SP, Kleiner DF, Fioravanti S, Walker M, Carey S, Figg WD, Steinberg SM, Anderson V. A pilot study of tremelimumab \u2013 a monoclonal antiboydi against CTLA-4 \u2013 in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2015;33:abstract 4081.","DOI":"10.1200\/jco.2015.33.15_suppl.4081"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"El-Khouciry AB, Melero I, Crocenzi TS, Welling III TH, Yau T, Yeo W, Chopra A, Grosso JF, Lang L, Anderson J. Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015;33:abstract LBA101.","DOI":"10.1200\/jco.2015.33.18_suppl.lba101"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.09.033"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.357"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12726"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0937"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2016.10.008"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5248"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28835"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S115727"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.10.003"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2016.08.054"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.6b09333"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.6b00197"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-016-7930-9"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3727\/105221616X693855"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0467-0"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1080\/13880209.2016.1214742"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.08.028"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0457-1"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3717"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5126"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.10.023"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.120"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605856"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgw118"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-016-0294-4"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13398"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.5497\/wjp.v3.i4.86"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.027"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.10.003"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30559"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-016-2253-6"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v9\/i21\/907.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:19:57Z","timestamp":1692904797000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v9\/i21\/907.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":116,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v9.i21.907","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}